New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations

CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients Brainwide RNA expression greater than 200-fold higher than AAV9, with significant detargeting of liver and DRGs with proprietary engineered capsid Company on track to file…